DIADIA0.64%
SPYSPY0.42%
QQQQQQ0.24%
Trending
Top trending tickerNVTSNVTS23.94%
GMEGME9.51%
MRVLMRVL5.47%
BBBB0.19%
AVGOAVGO0.33%
PANWPANW5.28%
USARUSAR3.75%
CMGCMG2.15%
SMRSMR8.89%
METAMETA3.39%
Top trending tickerNVTSNVTS23.94%
GMEGME9.51%
MRVLMRVL5.47%
BBBB0.19%
AVGOAVGO0.33%
PANWPANW5.28%
USARUSAR3.75%
CMGCMG2.15%
SMRSMR8.89%
METAMETA3.39%
CTNM logo

CTNMContineum Therapeutics Inc. - Ordinary Shares - Class A

$12.73
$0.35
(2.83%)
Today
Updated: 10:06 AM EDT
Reported EarningsMay 5
Mkt Cap$462.84M
Vol24,958.00
36

Bearish Sentiment

How do you feel about CTNM?

Feed

News

Sentiment

Earnings

Fundamentals

Info

News
all
press releases
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Here is how Adagene Inc. Sponsored ADR (ADAG) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.
Zacks
News Placeholder
More News
News Placeholder
Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the...
Business Wire
News Placeholder
Wall Street Analysts See a 59.96% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High?
The consensus price target hints at a 60% upside potential for Contineum Therapeutics, Inc. (CTNM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
News Placeholder
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire
News Placeholder
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Here is how C4 Therapeutics, Inc. (CCCC) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.
Zacks
News Placeholder
Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire
News Placeholder
Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire
News Placeholder
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 49.2% in Contineum Therapeutics, Inc. (CTNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
News Placeholder
Contineum Therapeutics (CTNM) Projected to Post Earnings on Wednesday
Contineum Therapeutics (NASDAQ:CTNM) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at...
MarketBeat
News Placeholder
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire
<
1
2
...
>
Top Discussions

Advertisement|Remove ads.